OptimizeRx (OptimizeRx) Interest Expense : $-1.45 Mil (TTM As of Dec. 2023)

View and export this data going back to 2009. Start your Free Trial

What is OptimizeRx Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. OptimizeRx's interest expense for the three months ended in Dec. 2023 was $ -1.45 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.45 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. OptimizeRx's Operating Income for the three months ended in Dec. 2023 was $ -2.02 Mil. OptimizeRx's Interest Expense for the three months ended in Dec. 2023 was $ -1.45 Mil. OptimizeRx did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

OptimizeRx Interest Expense Historical Data

The historical data trend for OptimizeRx's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OptimizeRx Interest Expense Chart

OptimizeRx Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-1.45

OptimizeRx Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Expense	Get a 7-Day Free Trial															-	-	-	-	-1.45

OptimizeRx Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.45 Mil.

OptimizeRx (NAS:OPRX) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

OptimizeRx's Interest Expense for the three months ended in Dec. 2023 was $-1.45 Mil. Its Operating Income for the three months ended in Dec. 2023 was $-2.02 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was $34.60 Mil.

OptimizeRx's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

OptimizeRx did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

OptimizeRx (OptimizeRx) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » OptimizeRx Corp (NAS:OPRX) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

400 Water Street, Suite 200, Rochester, MI, USA, 48307

Website

https://www.optimizerx.com

OptimizeRx Corp is engaged in the healthcare market in the United States. It provides digital health messaging via electronic health records, providing a direct channel for pharmaceutical companies to communicate with healthcare providers and patients. The cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and clinical information. Its products offering are Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement.

Executives

Marion Odence-ford	officer: General Counsel and CCO	400 WATER STREET, SUITE 200, ROCHESTER MI 48307
Theresa Greco	officer: Chief Commercial Officer	260 CHARLES STREET, SUITE 302, WALTHAM MA 02153
Doug Besch	officer: Chief Product Officer	400 WATER STREET, SUITE 200, ROCHESTER MI 48307
William J Febbo	officer: Chief Executive Officer	600 CALIFORNIA ST., 9TH FLOOR, SAN FRANCISCO CA 94108
James Paul Lang	director	C/O BIOVIE, 2120 COLORADO AVENUE, SUITE 230, SANTA MONICA CA 90404
Stephen L Silvestro	officer: Chief Commercial Officer	400 WATER STREET, SUITE 200, ROCHESTER MI 48307
Ellen O'connor Vos	director	C/O NTELOS HOLDINGS CORP., 1154 SHENANDOAH VILLAGE DRIVE, WAYNESBORO VA 22980
Edward Stelmakh	officer: COO and CFO	400 WATER STREET, SUITE 200, ROCHESTER MI 48307
Miriam J Paramore	officer: President	400 WATER STREET, SUITE 200, ROCHESTER MI 48307
Patrick D Spangler	director, officer: SVP of Product & Strategy	14405 21ST AVENUE NORTH, MINNEAPOLIS MN 55447
Douglas P Baker	officer: Chief Financial Officer	400 WATER STREET, SUITE 200, ROCHESTER MI 48307
Todd Inman	officer: Chief Technology Officer	400 WATER STREET, SUITE 200, ROCHESTER MI 48307
Gregory D Wasson	director	200 WILMOT ROAD, DEERFIELD IL 60015
Gus D Halas	director	38 PHEASANT RUN PLACE, DANVILLE CA 94506
Awm Investment Company, Inc.	10 percent owner	527 MADISON AVENUE, SUITE 2600, NEW YORK NY 10022